Trial NCT06118723
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- Phase
- Not given
- Sponsor
- Jasper Gerritsen
- Conditions
- Glioblastoma; High-grade Glioma; Glioblastoma, IDH-wildtype; Glioblastoma, IDH-mutant; Glioblastoma Multiforme, Adult; Astrocytoma, Grade IV; Astrocytoma, Grade III; Astrocytoma, Malignant; Brain Neoplasms; Brain Neoplasm, Primary; Brain Neoplasms, Adult; Brain Neoplasm, Malignant
- Ages
- 18–90 years
Eligibility criteria
Highlighted: restrictions our model extracted, each a verbatim quote (pink = excludes outright, blue = only under conditions).
Inclusion Criteria:
1. Age ≥18 years and ≤90 yearsAge
2. Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon
3. Written informed consent
Exclusion Criteria:
1. Tumors of the cerebellum, brainstem or midline
2. Multifocal contrast enhancing lesions
3. Medical reasons precluding MRI (e.g. pacemaker)
4. Inability to give written informed consent
5. Secondary high-grade glioma due to malignant transformation from low-grade glioma
6. Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skinPrior malignancy
Restrictions found (2)
- AgeOutrightinclusion
age <= 90
Show in the text - Prior malignancyOutrightexclusion
within 5 years
Show in the text
Recruiting in Massachusetts
- Massachusetts General Hospital · Boston, Suffolk County